osimertinib
NICE Backs AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC Through Cancer Drugs Fund
Since it's still uncertain whether the drug extends survival, the agency recommended access through the CDF while clinical trial data mature.
Hutchmed, AstraZeneca Begin Phase III Trial in NSCLC With EGFR, MET Mutations
The trial will evaluate Orpathys plus Tagrisso in patients with advanced or metastatic EGFR-positive, MET-amplified NSCLC who have progressed after EGFR inhibitor therapy.
Geneseeq Multi-Biomarker Approach Predicts EGFR-Mutated NSCLC Patients' Adjuvant Therapy Benefit
Premium
Geneseeq collaborated with researchers in China to generate three molecularly defined subgroups to guide adjuvant NSCLC treatment with either TKIs or chemotherapy.
AstraZeneca's Q3 Oncology Revenues Grow 18 Percent
The company's oncology segment contributed 34 percent of total revenues and brought in $3.38 billion during the quarter.
In Brief This Week: AstraZeneca, CytoDyn, BerGenBio, Bayer, Dana-Farber Cancer Institute, Kronos Bio
News items for the week of Nov 8, 2021.